The Readout Loud 319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
Aug 22, 2024
Discussing a significant leadership shift at BioMarin, the new chief business officer steps in as the company navigates challenges in gene therapy commercialization. New findings on Eli Lilly's obesity drug Zepbound reveal its potential to lower diabetes risk while raising concerns about mental health impacts. The conversation turns to Recursion Pharmaceuticals, exploring their innovative use of AI in drug development, skepticism about the technology's effectiveness, and insights into their unique headquarters designed for creativity and collaboration.
Chapters
Transcript
Episode notes